News | March 01, 2024
Pfizer Oncology hosts innovation day
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Comprehensive clinical development programs being initiated for each investigational candidate
Innovent will supply sintilimab for the collaborated clinical trial
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated
